We propose to evaluate changes in the microbiome in patients with ileal, colonic, and ileo-colonic Crohn’s Disease (CD) before and after adherence to the Anti-Inflammatory Diet (AID). We hypothesize that by following the IBD-AID, CD subjects will A) demonstrate a change in the pattern of the microbiome as measured at baseline and follow-up by the Electronic Nose (E-Nose, baseline is part of the parent study), and B) find improvement in symptomology as measured by the Harvey Bradshaw Index (HBI), a validated and reliable tool to measure health-related quality of life in adult patients with Crohn's disease (all subjects have filled this out as part of the parent study). Crohn’s subjects who meet eligibility but decline intervention will be invited to serve as controls.
Inflammatory Bowel Disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), are chronic non specific inflammatory conditions. Standard IBD treatment typically employs a combination of anti-inflammatory and immune suppressive medications; however, the pharmacological approach is not by itself curative. The Anti-Inflammatory Diet for IBD (IBD-AID), which is derived and augmented from The Specific Carbohydrate Diet (SCD), is a nutritional regimen that restricts the intake of complex carbohydrates such as refined sugar, gluten-based grains, and certain starches from the diet. These carbohydrates are thought to provide a substrate for pro-inflammatory bacteria. The second component of the diet involves the ingestion of pre-and probiotics to help restore an anti-inflammatory environment.
To assess the efficacy and feasibility of the Anti –Inflammatory Diet (IBD-AID) intervention for the treatment of IBD.
Please click on this link to view our poster abstract.